STAU1 (E5Z1N) Rabbit mAb #89056
- WB
Supporting Data
REACTIVITY | H Mk |
SENSITIVITY | Endogenous |
MW (kDa) | 63, 55 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Simple Western™ | 1:50 - 1:250 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
STAU1 is encoded by the STAU1 gene and is ubiquitously expressed in most cell and tissue types. Multiple isoforms of STAU1 have been identified due to alternative splicing, with the two predominant isoforms being STAU155 and STAU163 (3,4). STAU1 plays a key role in multiple RNA processes, including splicing, translation, targeted mRNA decay (referred to as Staufen-mediated mRNA decay or SMD), and the transport of mRNA to subcellular regions during embryonic development and differentiation (1,5-10). STAU1 also transports mRNA along neuronal dendrites, contributing to localized protein synthesis and synaptic plasticity (11,12). Indeed, STAU1-deficient mice display reduced dendritic protrusions and impaired dendritic outgrowth, resulting in fewer synapses (13). STAU1 can undergo liquid-liquid phase separation and is frequently recruited to cytoplasmic foci known as stress granules (SGs), which are ribonucleoprotein (RNP) granules formed at sites of stalled mRNA translation (14,15). STAU1 has also been found to interact with ataxin-2, another SG-associated protein that is the primary cause of spinocerebellar ataxia type 2 (SCA2) when mutated (16). Cells derived from SCA2 patients display elevated levels of STAU1 protein and colocalization between STAU1 and ataxin-2 in SG-like aggregates (16). Recruitment of STAU1 to pathological protein aggregates has also been observed in other neurological disorders, such as amyotrophic lateral sclerosis (ALS) (17). STAU1 function has additionally been implicated in several types of cancer, including prostate, colorectal, and glioma (18-20).
- St Johnston, D. et al. (1991) Cell 66, 51-63.
- Almasi, S. and Jasmin, B.J. (2021) Cell Mol Life Sci 78, 7145-7160.
- Wickham, L. et al. (1999) Mol Cell Biol 19, 2220-30.
- Bondy-Chorney, E. et al. (2016) Rare Dis 4, e1225644.
- Ravel-Chapuis, A. et al. (2012) J Cell Biol 196, 699-712.
- Dugré-Brisson, S. et al. (2005) Nucleic Acids Res 33, 4797-812.
- Kim, Y.K. et al. (2005) Cell 120, 195-208.
- Park, E. and Maquat, L.E. (2013) Wiley Interdiscip Rev RNA 4, 423-35.
- Broadus, J. et al. (1998) Nature 391, 792-5.
- Gautrey, H. et al. (2008) Biochim Biophys Acta 1783, 1935-42.
- Lebeau, G. et al. (2008) Mol Cell Biol 28, 2896-907.
- Heraud-Farlow, J.E. and Kiebler, M.A. (2014) Trends Neurosci 37, 470-9.
- Vessey, J.P. et al. (2008) Proc Natl Acad Sci USA 105, 16374-9.
- Thomas, M.G. et al. (2005) Mol Biol Cell 16, 405-20.
- Thomas, M.G. et al. (2009) J Cell Sci 122, 563-73.
- Paul, S. et al. (2018) Nat Commun 9, 3648.
- Paul, S. et al. (2021) Ann Neurol 89, 1114-1128.
- Marcellus, K.A. et al. (2021) BMC Cancer 21, 120.
- Damas, N.D. et al. (2016) Nat Commun 7, 13875.
- Jing, F. et al. (2020) Mol Ther Oncolytics 17, 216-231.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.